Related Experiment Videos
The relationship between natural killer cells and drugs that modify metastasis of PA-III cells
Abstract:
Rat prostate adenocarcinoma III (PA-III) cells produce in L-W rats local tumors at the implant site, osteolytic and osteoblastic lesions and metastatic tumors in the lungs. Treatment of rats with dichloromethylene diphosphonate (Cl2MDP) prevented the osteolytic lesions, but the drug showed little beneficial effect on the local and/or metastatic spread of tumor cells. While treatment of rats with piroxicam inhibited PA-III cell metastasis, it manifested only moderate protection against the development of osteolytic lesions. Treatments with both Cl2MDP and piroxicam resulted in smaller tumors, no osteolysis and significantly reduced metastasis. Comparisons of natural killer (NK) cell activities in normal and in tumor-bearing rats, with and without drug treatments, showed that NK cell activity was suppressed by Cl2MDP, and enhanced by piroxicam. When treatments included both drugs, NK cell activity was enhanced. Thus, the suppression of NK cell activity resulting from treatment with Cl2MDP was reversed by piroxicam with resultant benefits from both drugs.
Insights
Dichloromethylene diphosphonate (Cl2MDP) and piroxicam treatments reduced prostate cancer spread and bone lesions in rats. Combining both drugs enhanced natural killer (NK) cell activity, improving therapeutic outcomes.
Area of Science:
- Oncology
- Pharmacology
- Immunology
Background:
- Rat prostate adenocarcinoma III (PA-III) cells induce local tumors, osteolytic lesions, and lung metastasis in L-W rats.
- Osteolytic lesions are a significant complication of PA-III tumor progression.
- Metastasis and local tumor spread remain challenges in PA-III cancer treatment.
Purpose of the Study:
- To evaluate the efficacy of dichloromethylene diphosphonate (Cl2MDP) and piroxicam, alone and in combination, on PA-III tumor growth, metastasis, and bone lesions.
- To investigate the impact of these treatments on natural killer (NK) cell activity in tumor-bearing rats.
Main Methods:
- Administration of Cl2MDP and/or piroxicam to L-W rats bearing PA-III tumors.
- Assessment of local tumor size, osteolytic and osteoblastic lesions, and lung metastasis.
- Measurement of natural killer (NK) cell activity in treated and untreated tumor-bearing rats.
Main Results:
- Cl2MDP alone prevented osteolytic lesions but had minimal effect on tumor spread.
- Piroxicam alone inhibited metastasis but offered moderate protection against osteolytic lesions.
- Combined Cl2MDP and piroxicam treatment resulted in smaller tumors, no osteolysis, and significantly reduced metastasis.
- Cl2MDP suppressed NK cell activity, while piroxicam enhanced it; combined treatment enhanced NK cell activity.
Conclusions:
- Combined treatment with Cl2MDP and piroxicam offers superior therapeutic benefits for PA-III tumors compared to monotherapy.
- Piroxicam can reverse the immunosuppressive effects of Cl2MDP on NK cells, leading to improved anti-tumor outcomes.
- This combination therapy presents a promising strategy for managing prostate cancer with bone involvement and metastatic potential.